Kumar S, Zhu L J, Polihronis M, Cameron S T, Baird D T, Schatz F, Dua A, Ying Y K, Bagchi M K, Bagchi I C
Population Council and The Rockefeller University, New York, New York 10021, USA.
J Clin Endocrinol Metab. 1998 Dec;83(12):4443-50. doi: 10.1210/jcem.83.12.5328.
The human endometrium acquires the ability to implant the developing embryo within a specific time window that is thought to open between days 19-24 of the secretory phase of the menstrual cycle. During this period the endometrium undergoes pronounced structural and functional changes induced by the ovarian steroids, estrogen and progesterone, that prepare it to be receptive to invasion by the embryo. The identification of reliable biochemical markers to assess this critical receptive phase in the context of the natural cycle remains one of the major challenges in the study of human reproduction. Our previous studies in a rat model system demonstrated that the expression of calcitonin, a peptide hormone involved in calcium homeostasis, is transiently induced by progesterone in the glandular epithelium at the onset of implantation. Attenuation of calcitonin synthesis in the uterus during the preimplantation phase by administration of calcitonin antisense oligodeoxynucleotides severely impairs implantation of rat embryos, suggesting that this peptide hormone plays a critical role in uterine receptivity. To investigate whether calcitonin is also expressed in the human endometrium during implantation, we monitored the spatio-temporal expression of calcitonin on various days of the menstrual cycle. Our studies employing RT-PCR showed that calcitonin messenger ribonucleic acid is expressed in human endometrium during the postovulatory midsecretory phase (days 17-25) of the menstrual cycle, with maximal expression occurring between days 19-21. Very little calcitonin expression was detected in the endometrium in either the preovulatory proliferative (days 5-14) or the late secretory (days 26-28) phase. In situ hybridization and immunocytochemical analyses localized the calcitonin expression predominantly in the glandular epithelial cells of the endometrium. Our studies further showed that calcitonin expression in the human endometrium is under progesterone regulation. Treatment of women with an antiprogestin, mifepristone (RU-486), drastically reduced calcitonin expression in the endometrium. Collectively, these findings reveal that progesterone-induced expression of calcitonin in the secretory endometrium temporally coincides with the putative window of implantation in the human.
人类子宫内膜在月经周期分泌期第19至24天之间被认为会打开的特定时间窗内获得植入发育中胚胎的能力。在此期间,子宫内膜会经历由卵巢类固醇激素雌激素和孕激素诱导的显著结构和功能变化,从而使其为胚胎的侵入做好准备。在自然周期背景下鉴定可靠的生化标志物以评估这一关键的接受期,仍然是人类生殖研究中的主要挑战之一。我们之前在大鼠模型系统中的研究表明,降钙素(一种参与钙稳态的肽类激素)的表达在植入开始时由孕激素在腺上皮中短暂诱导。在植入前阶段通过给予降钙素反义寡脱氧核苷酸来减弱子宫中降钙素的合成,会严重损害大鼠胚胎的植入,这表明这种肽类激素在子宫接受性中起关键作用。为了研究植入期间降钙素在人类子宫内膜中是否也有表达,我们监测了月经周期不同天数降钙素的时空表达。我们采用逆转录聚合酶链反应(RT-PCR)的研究表明,降钙素信使核糖核酸在月经周期排卵后中期分泌期(第17至25天)的人类子宫内膜中表达,在第19至21天表达量最高。在排卵前增殖期(第5至14天)或分泌晚期(第26至28天)的子宫内膜中几乎检测不到降钙素表达。原位杂交和免疫细胞化学分析将降钙素表达主要定位在子宫内膜的腺上皮细胞中。我们的研究进一步表明,人类子宫内膜中降钙素的表达受孕激素调节。用抗孕激素米非司酮(RU-486)治疗女性会大幅降低子宫内膜中降钙素的表达。总的来说,这些发现揭示了孕激素诱导的降钙素在分泌期子宫内膜中的表达在时间上与人类假定的植入窗一致。